Zahn T P, Insel T R, Murphy D L
Br J Psychiatry. 1984 Jul;145:39-44. doi: 10.1192/bjp.145.1.39.
Twelve patients with obsessive compulsive disorder were studied with psychophysiological measures during a randomised, double-blind placebo-controlled drug trial. Significant clinical improvement followed six weeks of treatment with the tricyclic antidepressant clomipramine, but was not evident after an equal period of treatment with the monoamine oxidase inhibitor (MAOI) clorgyline. Compared to placebo, both drugs reduced skin conductance indices of baseline arousal, but only clomipramine reduced skin conductance and heart rate responses to loud tones and tonic and phasic skin conductance responses in a two-flash discrimination task. This suggests that reductions in autonomic responses to important and/or aversive stimuli may be critical to clinical improvement in obsessive compulsive disorder.
在一项随机、双盲、安慰剂对照药物试验中，对12名强迫症患者进行了心理生理学测量研究。使用三环类抗抑郁药氯米帕明治疗六周后，患者有显著的临床改善，但使用单胺氧化酶抑制剂（MAOI）氯吉兰进行相同疗程的治疗后，改善并不明显。与安慰剂相比，两种药物均降低了基线觉醒的皮肤电导率指标，但只有氯米帕明降低了对响亮声音的皮肤电导率和心率反应，以及在双闪光辨别任务中的紧张性和相位性皮肤电导率反应。这表明，对重要和/或厌恶刺激的自主反应降低可能对强迫症的临床改善至关重要。
